Information With or Without Numbers For Optimizing Reasoning About Medical Decisions
| Status: | Completed |
|---|---|
| Conditions: | Colorectal Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 50 - 75 |
| Updated: | 9/30/2017 |
| Start Date: | June 2015 |
| End Date: | August 25, 2017 |
Describing the Comparative Effectiveness of Colorectal Cancer Screening Tests: The Impact of Quantitative Information
Experts believe that increasing the low uptake of screening for colorectal cancer (CRC)
requires educating patients about all approved tests and helping them choose one that fits
their preferences. As one motto puts it: "The best test is the one that gets done." Screening
tests range from more invasive and very sensitive for polyps and cancer (colonoscopy) to less
invasive and less sensitive (e.g., fecal immunochemical testing (FIT)). But it is unclear how
best to educate patients about the options and the tradeoffs involved. Some guidelines
recommend that decision aids, a promising tool in this area, provide patients with detailed
quantitative information, including baseline risk, risk reduction, and chance of negative
outcomes. But this sort of "comparative effectiveness" data can confuse patients, especially
those with limited mathematical ability. Previous studies have not measured the effect of
providing quantitative information to patients with varying levels of ability or interest or
asked them whether such data is essential for their decision-making.
The investigators will conduct a clinical trial to determine the impact on patients who view
a decision aid (DA) that includes quantitative information versus a DA without such data. The
investigators will also seek to determine whether numeracy moderates the effect of
quantitative information.
requires educating patients about all approved tests and helping them choose one that fits
their preferences. As one motto puts it: "The best test is the one that gets done." Screening
tests range from more invasive and very sensitive for polyps and cancer (colonoscopy) to less
invasive and less sensitive (e.g., fecal immunochemical testing (FIT)). But it is unclear how
best to educate patients about the options and the tradeoffs involved. Some guidelines
recommend that decision aids, a promising tool in this area, provide patients with detailed
quantitative information, including baseline risk, risk reduction, and chance of negative
outcomes. But this sort of "comparative effectiveness" data can confuse patients, especially
those with limited mathematical ability. Previous studies have not measured the effect of
providing quantitative information to patients with varying levels of ability or interest or
asked them whether such data is essential for their decision-making.
The investigators will conduct a clinical trial to determine the impact on patients who view
a decision aid (DA) that includes quantitative information versus a DA without such data. The
investigators will also seek to determine whether numeracy moderates the effect of
quantitative information.
Inclusion Criteria:
1. Have not had colonoscopy performed in last 10 years, sigmoidoscopy in last 5 years, or
fecal occult blood testing (including FIT) in last 1 year and
2. have a scheduled appointment or due to schedule an appointment with a healthcare
practitioner at our performance sites.
Exclusion Criteria:
1. undergoing workup for symptoms consistent with colon cancer, such as weight loss or
rectal bleeding
2. have a diagnosis or medical history conferring elevated risk for CRC including
polypectomy or colon cancer, inflammatory bowel disease, certain inherited syndromes,
or a significant family history of CRC
3. are unable to speak and read English.
We found this trial at
1
site
Indiana University INDIANA UNIVERSITY is a major multi-campus public research institution, grounded in the liberal...
Click here to add this to my saved trials
